Celgene Reports Otezla (apremilast) Achieve 1EP in P-III STYLE Study to Treat Moderate-to-Severe Scalp Psoriasis

 Celgene Reports Otezla (apremilast) Achieve 1EP in P-III STYLE Study to Treat Moderate-to-Severe Scalp Psoriasis

Celgene Reports Otezla (apremilast) Achieve 1EP in P-III STYLE Study to Treat Moderate-to-Severe Scalp Psoriasis

Shots:

  • The P-III STYLE study involves assessing of Otezla 30mg bid vs PBO in moderate to severe plaque psoriasis patients in ratio (2:1) for 16 wks., evaluating its safety and efficacy
  • P-III STYLE study results(N=300): improvement in 1EP of the ScPGA response (clear (0)/almost (1)/at least (2-point reduction)) @16wks.; met 2EP of whole body itch with NRS scale@16wks.; no new safety signals identified
  • Otezla 30 mg is an oral small molecule PDE4i specific for cAMP, indicated for treatment of moderate-to-severe plaque psoriasis

Click here to read full press release/ article | Ref: Celgene | Image: Knowledge Ecology International

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post